• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

US Drugmaker Trevena’s Ultra-Strong Painkiller Begins Final-Stage Trials in China

firstwordpharmaJuly 08, 2021

Tag: Trevena , TRV-130 , FDA

Treneva's TRV-130 has entered Phase III trials in China, as reported Yicai Global on Wednesday.

TRV-130, which was approved by the FDA last year, is used to treat moderate to severe acute pain in adults.

The company's Chinese partner Jiangsu Nhwa Pharmaceutical said that tests have begun on the first volunteer in trials at the Third Xiangya Hospital of Central South University in Changsha, central Hunan province.


Previous:Stealth BioTherapeutics Joins the Rare Disease Company Coalition

Next:Absci Strengthens Executive Leadership Team

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

US Drugmaker Trevena’s Ultra-Strong Painkiller Begins Final-Stage Trials in China | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Tobramycin base( FDA)

Tobramycin base( FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)
Vecuronium (FDA)

Vecuronium (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service